DOI: 10.1007/s00259-018-3997-0Pages: 1-11

Prognostic value of [18F]FDG-PET/CT in multiple myeloma patients before and after allogeneic hematopoietic cell transplantation

1. University Hospital Würzburg, Medical Center, Department of Nuclear Medicine

2. University of California Los Angeles, Department of Molecular & Medical Pharmacology, Ahmanson Translational Imaging Division

3. University of Ulm, Medical Center, Department of Nuclear Medicine

4. University Hospital Würzburg, Department of Internal Medicine II, Hematology and Oncology

5. University of Ulm, Medical Center, Department of Internal Medicine III, Hematology and Oncology

6. University Hospital Heidelberg, Department of Internal Medicine V

Correspondence to:
Constantin Lapa
Tel: +49(0)931-201-35412
Email: lapa_C@ukw.de

Close

Abstract

Purpose

Despite improved treatment options, multiple myeloma (MM) remains an incurable disease. The aim of this study was to investigate the prognostic value of positron emission tomography/computed tomography (PET/CT) using 18F-2’-deoxy-2’-fluorodeoxyglucose ([18F]FDG) in MM patients shortly before and ~100 days after allogeneic hematopoietic cell transplantation (allo-HCT).

Methods

In this retrospective analysis, we evaluated [18F]FDG-PET/CT-scans of 45 heavily pre-treated MM patients before and 27 patients after scheduled allo-HCT. All scans were qualitatively and semi-quantitatively assessed for the presence of active disease. Serological response was recorded according to International Myeloma Working Group (IMWG) criteria. Progression-free (PFS) and overall survival (OS) were correlated with different PET/CT-derived parameters, such as presence, number and maximum standardized uptake value (SUVmax) of focal myeloma lesions. The impact of extramedullary disease on patient outcome was also assessed.

Results

PET/CT negativity -prior to or following allo-HCT- was a favorable prognostic factor for progression-free and overall survival (both, PFS and OS: pre-HSCT p < 0.001, post-HCT p < 0.005). High FDG-uptake (SUVmax > 6.5) revealed a significantly shortened survival compared to patients with a lower SUVmax (<6.5) (OS, 5.0 ± 1.1 m vs. not reached - longest 122.0 m; p < 0.001). Moreover, our data prove that a higher number (>3) of focal lesions (pre-HCT: both PFS and OS: p < 0.001; post-HCT PFS: p < 0.001, OS: p = 0.139) as well as the presence of extramedullary disease serve as adverse prognostic factors prior to and after allo-HCT. At response assessment after allo-HCT, [18F]FDG-PET/CT had a complementary value in prognostication in addition to IMWG criteria alone.

Conclusion

[18F]FDG-PET/CT before and shortly after allogeneic HCT is a powerful predictor for progression-free and overall survival in MM patients.

To access the full text, please Sign in

If you have institutional access, please click here

  • Accepted: Mar 21, 2018
  • Online: Apr 2, 2018

Article Tools

eanm
EJNMMI Ad